Biogen Competitive Intelligence & Landscape

Founded in 1978, Biogen biogen.com is a leading biotechnology company dedicated to pioneering innovative science to deliver new medicines that transform patients’ lives. The company focuses on developing breakthrough therapies in neurology, immunology, and rare diseases.

Biogen aims to make breakthroughs happen for hard-to-treat diseases through scientific curiosity and a commitment to helping people globally.

Biogen’s mission is to deliver new medicines to transform patients' lives, rooted in its legacy of pursuing biological breakthroughs since its inception. The company is headquartered in Cambridge, MA, USA, with an international headquarters in Baar, Switzerland https://www.biogen.com/company/contact-us.html. Their core value proposition emphasizes bold risks balanced with return on investment to deliver long-term value for shareholders and communities https://www.biogen.com/company.html.

The company's target market includes patients suffering from diseases such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Friedreich Ataxia, Kidney Disease, Lupus, Multiple Sclerosis, Postpartum Depression, and Spinal Muscular Atrophy.

Biogen provides various medicines and therapies to improve the well-being of people around the world, with a focus on U.S. residents for specific product information https://www.biogen.com/medicines.html.

Biogen's product and pricing intelligence is centered around ensuring access to its innovative therapies, particularly in neurology, specialized immunology, and rare diseases [source]. The company offers a range of medicines including LEQEMBI, ZURZUVAE, SKYCLARYS, SPINRAZA, QALSODY, and VUMERITY, which serve as commercial-stage growth products [source].

Biogen does not offer traditional tiered pricing plans or free-to-paid features common in software services. Instead, its focus is on patient access and health equity [source]. The company emphasizes that the prices of its medicines reflect their unique advancements in improving patient health and clinical outcomes [source]. To support this, Biogen provides a comprehensive suite of financial assistance tools to help patients and healthcare professionals understand and select insurance options and programs [source].

Recent pricing changes include a significant reduction in the wholesale acquisition cost (WAC) of ADUHELM® (aducanumab-avwa) by approximately 50%, effective January 1, 2022. This change aimed to lower out-of-pocket expenses for patients, with the yearly cost for an average patient at the maintenance dose set at $28,200 [source]. Furthermore, Biogen collaborates with initiatives like CVS Health's Project Health to offer cognitive screenings, particularly in underserved communities, as part of broader access efforts for treatments like ADUHELM® [source].

For investigational drugs, Biogen primarily provides access through clinical trials [source]. The company's Early Access Programs are designed to make medicines available to the greatest number of patients in a timely manner, with trials testing safety and effectiveness for regulatory approval [source].

Biogen also maintains a Developer Portal I/O Docs that provides API documentation, which can be accessed after signing in or registering [source].

Biogen actively recruits for a diverse range of roles, emphasizing a commitment to attracting and developing "courageous and collaborative talent" with a "diversity of perspectives and backgrounds" [biogen.com/careers/career-categories.html]. The company's hiring process, which can vary by position and region, begins with an application submitted through their career opportunities portal [biogen.com/careers/how-we-hire.html]. While specific recent hiring trends or layoffs are not detailed on their career pages, the comprehensive information provided suggests a continuous effort to build its workforce, especially within critical areas like Human Resources, which is noted for driving strategic decision-making and business strategy forward [biogen.com/careers/career-categories.html].

Biogen is particularly focused on nurturing future talent through various student and graduate programs. These include summer internships and six-month co-ops for college and university students across all degree types, offering invaluable experience in the pharmaceutical and biotech industry [biogen.com/careers/students-and-graduates.html]. Furthermore, the company collaborates with MCPHS University to offer seven unique PharmD Fellowship programs, promoting the role of the Doctor of Pharmacy within the biopharmaceutical industry in areas such as Regulatory Sciences, Worldwide Medical, and U.S. Marketing [biogen.com/careers/students-and-graduates/pharmd-fellowships.html].

Additionally, Biogen offers a two-year Ph.D. Fellowship in Worldwide Medical, providing recent doctoral graduates with hands-on experience in medical affairs and the pharmaceutical industry. This fellowship, which enrolls a new cohort annually in July, serves as an accelerated introduction to a career in medical affairs within a cutting-edge biotech company [biogen.com/careers/students-and-graduates/phd-fellowship.html]. These structured programs signal Biogen's strategic investment in long-term talent acquisition and development, ensuring a pipeline of skilled professionals to support its mission of making breakthroughs happen for hard-to-treat diseases [biogen.com].

While the public-facing career pages do not explicitly mention recent large-scale layoffs, the emphasis on a robust and diverse hiring process suggests an ongoing effort to maintain a strong workforce aligned with their scientific innovation and pipeline development in neurology, immunology, and rare diseases [biogen.com]. The company's global presence, with headquarters in Cambridge, MA, USA, and Baar, Switzerland, also indicates a wide array of career opportunities across different regions and functions [biogen.com/company/contact-us.html].

In 2024, Biogen reported total revenue of $9.7 billion, a 2% decline year-over-year. Despite this, GAAP diluted EPS grew by 40% to $11.18, and Non-GAAP diluted EPS increased by 12% to $16.47 [https://investors.biogen.com/node/28851/html]. The fourth quarter of 2024 saw total revenue of $2.5 billion, marking a 3% year-over-year growth [https://investors.biogen.com/node/28851/html].

Looking ahead, Biogen generated $9.9 billion in total revenue in the last year, with growth products showing a 19% year-over-year increase [https://investors.biogen.com/static-files/05644731-d13f-4279-8f89-304fa1e48827]. The company has also achieved $1 billion in gross operating expense savings through its Fit for Growth initiative, which commenced in 2023. This initiative included a 27% reduction in research and development (R&D) spending, allowing resources to be redirected to areas with higher return potential [https://investors.biogen.com/static-files/05644731-d13f-4279-8f89-304fa1e48827].

Biogen is committed to delivering long-term value for stockholders, driven by a strong late-stage pipeline that aims for both significant innovation and sustained growth [https://investors.biogen.com/node/30521/html]. The company's core pharmaceutical business experienced growth for the first time in four years, attributed to consistent revenue growth from ongoing product launches and strategic implementations expected to carry momentum through 2025 and beyond [https://investors.biogen.com/static-files/bf319499-564e-4bde-9dd6-6e1dd5314d6b].

Biogen (biogen.com) actively engages in a variety of investor and industry events, including earnings calls, annual stockholder meetings, and presentations at major healthcare conferences. For instance, the company is scheduled to host its Q2 2026 Earnings Call Webcast on July 29, 2026, and previously held its Annual Stockholder Meeting on June 9, 2026 biogen.com/events-presentations/events. These events provide important updates to shareholders and the broader financial community regarding the company's performance and strategic direction.

Biogen frequently participates in prominent healthcare industry conferences, where its executives present on various topics, often including fireside chats. Examples include presentations at the Bank of America Securities 2026 Health Care Conference biogen.com/events/event-details/biogen-present-bank-america-securities-2026-health-care-conference and participation in the Piper Sandler 37th Annual Healthcare Conference biogen.com/events/event-details/biogen-participating-piper-sandler-37th-annual-healthcare-conference. These engagements are crucial for communicating with investors and industry peers about Biogen's advancements and strategic outlook.

Furthermore, Biogen executives, such as Christopher A. Viehbacher, President and CEO, and other key leaders, regularly participate in investor conferences to discuss the company's portfolio and pipeline. Notable participations include the TD Cowen 46th Annual Health Care Conference biogen.com/news-releases/news-release-details/biogen-participate-td-cowen-46th-annual-health-care-conference, the Leerink Global Healthcare Conference 2026 biogen.com/news-releases/news-release-details/biogen-participate-leerink-global-healthcare-conference-2026, and the 44th Annual J.P. Morgan Healthcare Conference biogen.com/news-releases/news-release-details/biogen-present-44th-annual-jp-morgan-healthcare-conference. These appearances highlight Biogen's commitment to transparent communication and engagement with the investment community. The company also participates in specialized forums like the Stifel 2026 Virtual CNS Forum, where leaders discuss specific therapeutic areas biogen.com/news-releases/news-release-details/biogen-participate-stifel-2026-virtual-cns-forum.